Drug Candidate (undisclosed)
Improvement of endometrial receptivity for embryo implantation
Phase 3Active
Key Facts
Indication
Improvement of endometrial receptivity for embryo implantation
Phase
Phase 3
Status
Active
Company
About Vitrolife AB
Vitrolife AB is a Swedish public company and a dominant, fully integrated platform provider in the global assisted reproductive technology (ART) market. Founded in 1994, the company has evolved from a media specialist into a strategic partner for fertility clinics through a combination of organic innovation and strategic acquisitions, most notably of Igenomix. Its strategy focuses on offering complementary products and services across the entire IVF journey—from oocyte retrieval to embryo transfer and genetic testing—to improve success rates and lab efficiency, underpinned by a deep commitment to quality and clinical support.
View full company profile